Karin Larsson

Om mig
Publikationer
Populärvetenskap och samverkan

Om mig

Karin Larsson avslutade sin doktorsexamen inom bioteknologi år 2010. Hon fokuserade på produktionen och karakteriseringen av antikroppar för proteomikforskning som en del av Human Protein Atlas-projektet vid Kungliga Tekniska högskolan. Efter doktorsexamen började hon som postdoktor vid Karolinska Institutet på Institutionen för Mikrobiologi, Tumör- och Cellbiologi 2011. Hon flyttade sedan till Institutionen för Medicin, Solna först som postdoktor och sedan som Forskarassistent 2017, en tjänst finansierad av Barncancerfonden.

Forskningsbeskrivning

Karin Larssons forskning inom onkologi fokuserar på prostaglandiners och inflammationens roll i cancerutveckling och hur prostaglandiner påverkar tumörens mikromiljö. Hon använder cellulära 3D modeller för att förstå dynamiken bakom cancerutveckling och terapisvar. Hennes mål är att hitta nya terapeutiska mål för att övervinna resistens mot behandling och förbättra patientresultat.

Undervisning

Utöver hennes forskningsverksamhet har Karin Larsson genomfört flera kurser om undervisning på högskolenivå och deltar som lärare i kurser på kandidat-, magister- och forskarnivå.

Utvalda publikationer

Article: MOLECULAR ONCOLOGY. 2024;18(2):317-335

High-content screening of drug combinations of an mPGES-1 inhibitor in multicellular tumor spheroids leads to mechanistic insights into neuroblastoma chemoresistance.

Zaghmi A; Aybay E; Jiang L; Shang M; Steinmetz-Späh J; Wermeling F; Kogner P; Korotkova M; Östling P; Jakobsson P-J; Seashore-Ludlow B; Larsson K
Article: FASEB JOURNAL. 2020;34(8):11101-11114

Establishment of an in vitro 3D model for neuroblastoma enables preclinical investigation of combined tumor-stroma drug targeting.

Kock A; Bergqvist F; Steinmetz J; Elfman LHM; Korotkova M; Johnsen JI; Jakobsson P-J; Kogner P; Larsson K
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2019;176(24):4625-4638

Biological characterization of new inhibitors of microsomal PGE synthase-1 in preclinical models of inflammation and vascular tone.

Larsson K; Steinmetz J; Bergqvist F; Arefin S; Spahiu L; Wannberg J; Pawelzik S-C; Morgenstern R; Stenberg P; Kublickiene K; Korotkova M; Jakobsson P-J
Article: EBIOMEDICINE. 2018;32:84-92

Inhibition of Microsomal Prostaglandin E Synthase-1 in Cancer-Associated Fibroblasts Suppresses Neuroblastoma Tumor Growth.

Kock A; Larsson K; Bergqvist F; Eissler N; Elfman LHM; Raouf J; Korotkova M; Johnsen JI; Jakobsson P-J; Kogner P
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2015;112(26):8070-8075

COX/mPGES-1/PGE2 pathway depicts an inflammatory-dependent high-risk neuroblastoma subset.

Larsson K; Kock A; Idborg H; Arsenian Henriksson M; Martinsson T; Johnsen JI; Korotkova M; Kogner P; Jakobsson P-J

Artiklar

Article: FRONTIERS IN PHARMACOLOGY. 2023;14:1183720

The multiple functions of miR-574-5p in the neuroblastoma tumor microenvironment

Proestler E; Donzelli J; Nevermann S; Breitwieser K; Koch LF; Best T; Fauth M; Wickstrom M; Harter PN; Kogner P; Lavieu G; Larsson K; Saul MJ
Article: JOURNAL OF LIPID RESEARCH. 2022;63(12):100310

Biosynthesis of prostaglandin 15dPGJ2 -glutathione and 15dPGJ2-cysteine conjugates in macrophages and mast cells via MGST3.

Steinmetz-Späh J; Liu J; Singh R; Ekoff M; Boddul S; Tang X; Bergqvist F; Idborg H; Heitel P; Rönnberg E; Merk D; Wermeling F; Haeggström JZ; Nilsson G; Steinhilber D; Larsson K; Korotkova M; Jakobsson P-J
Article: BRITISH JOURNAL OF PHARMACOLOGY. 2022;179(7):1433-1449

Effects of microsomal prostaglandin E synthase-1 inhibition on resistance artery tone in patients with end stage kidney disease.

Steinmetz-Späh J; Arefin S; Larsson K; Jahan J; Mudrovcic N; Wennberg L; Stenvinkel P; Korotkova M; Kublickiene K; Jakobsson P-J
Article: JOURNAL OF EXTRACELLULAR VESICLES. 2021;10(12):e12143

Small extracellular vesicle-derived miR-574-5p regulates PGE2-biosynthesis via TLR7/8 in lung cancer.

Donzelli J; Proestler E; Riedel A; Nevermann S; Hertel B; Guenther A; Gattenlöhner S; Savai R; Larsson K; Saul MJ
Article: EMBO REPORTS. 2021;22(3):e51329

Phosphodiesterase 4A confers resistance to PGE2-mediated suppression in CD25+ /CD54+ NK cells.

Chen Z; Yang Y; Neo SY; Shi H; Chen Y; Wagner AK; Larsson K; Tong L; Jakobsson P-J; Alici E; Wu J; Cao Y; Wang K; Liu LL; Mao Y; Sarhan D; Lundqvist A
Article: FRONTIERS IN PHARMACOLOGY. 2019;10:636

Inhibition of mPGES-1 or COX-2 Results in Different Proteomic and Lipidomic Profiles in A549 Lung Cancer Cells.

Bergqvist F; Ossipova E; Idborg H; Raouf J; Checa A; Englund K; Englund P; Khoonsari PE; Kultima K; Wheelock CE; Larsson K; Korotkova M; Jakobsson P-J
Article: NATURE COMMUNICATIONS. 2018;9(1):1107

A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Pastor Fernández A; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Färnegårdh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Håkansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Laín S
Article: CLINICAL SCIENCE. 2016;130(24):2295-2303

Deletion of mPGES-1 affects platelet functions in mice.

Raouf J; Mobarrez F; Larsson K; Jakobsson P-J; Korotkova M
Article: PROSTAGLANDINS & OTHER LIPID MEDIATORS. 2015;120:161-165

Inhibition of microsomal prostaglandin E synthase-1 as targeted therapy in cancer treatment.

Larsson K; Jakobsson P-J
Article: PLOS ONE. 2014;9(5):e97285

Targeting of the MYCN protein with small molecule c-MYC inhibitors.

Müller I; Larsson K; Frenzel A; Oliynyk G; Zirath H; Prochownik EV; Westwood NJ; Henriksson MA
Article: PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA. 2013;110(25):10258-10263

MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells.

Zirath H; Frenzel A; Oliynyk G; Segerström L; Westermark UK; Larsson K; Munksgaard Persson M; Hultenby K; Lehtiö J; Einvik C; Påhlman S; Kogner P; Jakobsson P-J; Henriksson MA
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2011;370(1-2):14-23

Novel antigen design for the generation of antibodies to G-protein-coupled receptors.

Larsson K; Hofström C; Lindskog C; Hansson M; Angelidou P; Hökfelt T; Uhlén M; Wernérus H; Gräslund T; Hober S
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2009;342(1-2):20-32

Characterization of PrEST-based antibodies towards human Cytokeratin-17.

Larsson K; Eriksson C; Schwenk JM; Berglund L; Wester K; Uhlén M; Hober S; Wernérus H
Article: JOURNAL OF IMMUNOLOGICAL METHODS. 2006;315(1-2):110-120

Multiplexed PrEST immunization for high-throughput affinity proteomics.

Larsson K; Wester K; Nilsson P; Uhlén M; Hober S; Wernérus H
Article: MOLECULAR & CELLULAR PROTEOMICS. 2005;4(12):1920-1932

A human protein atlas for normal and cancer tissues based on antibody proteomics.

Uhlén M; Björling E; Agaton C; Szigyarto CA-K; Amini B; Andersen E; Andersson A-C; Angelidou P; Asplund A; Asplund C; Berglund L; Bergström K; Brumer H; Cerjan D; Ekström M; Elobeid A; Eriksson C; Fagerberg L; Falk R; Fall J; Forsberg M; Björklund MG; Gumbel K; Halimi A; Hallin I; Hamsten C; Hansson M; Hedhammar M; Hercules G; Kampf C; Larsson K; Lindskog M; Lodewyckx W; Lund J; Lundeberg J; Magnusson K; Malm E; Nilsson P; Odling J; Oksvold P; Olsson I; Oster E; Ottosson J; Paavilainen L; Persson A; Rimini R; Rockberg J; Runeson M; Sivertsson A; Sköllermo A; Steen J; Stenvall M; Sterky F; Strömberg S; Sundberg M; Tegel H; Tourle S; Wahlund E; Waldén A; Wan J; Wernérus H; Westberg J; Wester K; Wrethagen U; Xu LL; Hober S; Pontén F
Article: PROTEOMICS. 2005;5(17):4327-4337

Towards a human proteome atlas: high-throughput generation of mono-specific antibodies for tissue profiling.

Nilsson P; Paavilainen L; Larsson K; Odling J; Sundberg M; Andersson A-C; Kampf C; Persson A; Al-Khalili Szigyarto C; Ottosson J; Björling E; Hober S; Wernérus H; Wester K; Pontén F; Uhlen M

Alla övriga publikationer

Corrigendum: NATURE COMMUNICATIONS. 2023;14(1):5019

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Fernández AP; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Färnegårdh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Håkansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Laín S
Published paper: CELL BIOLOGY AND TRANSLATIONAL MEDICINE, VOL 14: STEM CELLS IN LINEAGE SPECIFIC DIFFERENTIATION AND DISEASE. 2019;1161:89-100

Targeting the COX/mPGES-1/PGE2 Pathway in Neuroblastoma.

Larsson K; Kock A; Kogner P; Jakobsson P-J
Corrigendum: NATURE COMMUNICATIONS. 2018;9(1):2071

Publisher Correction: A DHODH inhibitor increases p53 synthesis and enhances tumor cell killing by p53 degradation blockage.

Ladds MJGW; van Leeuwen IMM; Drummond CJ; Chu S; Healy AR; Popova G; Pastor Fernández A; Mollick T; Darekar S; Sedimbi SK; Nekulova M; Sachweh MCC; Campbell J; Higgins M; Tuck C; Popa M; Safont MM; Gelebart P; Fandalyuk Z; Thompson AM; Svensson R; Gustavsson A-L; Johansson L; Färnegårdh K; Yngve U; Saleh A; Haraldsson M; D'Hollander ACA; Franco M; Zhao Y; Håkansson M; Walse B; Larsson K; Peat EM; Pelechano V; Lunec J; Vojtesek B; Carmena M; Earnshaw WC; McCarthy AR; Westwood NJ; Arsenian-Henriksson M; Lane DP; Bhatia R; McCormack E; Laín S

Om mig

Forskningsbeskrivning

Undervisning

Utvalda publikationer

Artiklar

Alla övriga publikationer

Nyheter från KI

Kalenderhändelser från KI